All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
WASHINGTON — The medical technology sector has been plagued recently by myriad issues that have conspired to make the industry a tough sell to the investment community. Iian Scott, lead analyst for Ernst & Young's (EY; London) Lifescience group, called the three primary problems a "perfect storm for the industry."